Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 5/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | PIK3R2 | O00459 | 2/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | MERTK | Q12866 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185781 | 1.00 | PIK3CG (0.45) | PIK3CGPIK3CDPIK3CAPIK3CBMAP4K4 | |
| SCHEMBL17461779 | 0.94 | PIK3CD (0.42) | PIK3CGPIK3CDPIK3CAPIK3CBMAP4K4 | |
| SCHEMBL4176565 | 0.94 | PIK3CD (0.46) | PIK3CGPIK3CDPIK3CAPIK3CBMAP4K4 | |
| SCHEMBL27781185 | 0.93 | PIK3CD (0.49) | PIK3CGPIK3CDPIK3CAPIK3CBMAP4K4 | |
| SCHEMBL4184810 | 0.93 | PIK3CD (0.49) | PIK3CGPIK3CDPIK3CAPIK3CBMAP4K4 | |
| SCHEMBL4173435 | 0.91 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R2 | |
| SCHEMBL4173430 | 0.91 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R2 | |
| SCHEMBL12004856 | 0.91 | PIK3CD (0.56) | PIK3CGPIK3CDPIK3CAPIK3CBMAP4K4 | |
| SCHEMBL12014785 | 0.90 | PIK3CG (0.46) | PIK3CGPIK3CDPIK3CAPIK3CBMAP4K4 | |
| SCHEMBL4167490 | 0.87 | PIK3CG (0.44) | PIK3CGPIK3CDPIK3CAPIK3CBMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| EP-3179992-B1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PD-1 INHIBITOR AND/OR A PD-L1 INHIBITOR | ACERTA PHARMA BV (NL) | 2022-05-11 | — | — | EP | disclosed |
| US-20220088013-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA B.V. (NL) | 2022-03-24 | — | — | US | disclosed |
| US-20220054472-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC. | 2022-02-24 | — | — | US | disclosed |
| US-11166951-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2021-11-09 | — | — | US | disclosed |
| EP-3179991-B1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR AND A BCL-2 INHIBITOR | ACERTA PHARMA BV (NL) | 2021-10-06 | — | — | EP | disclosed |
| CN-112804994-A | Method for treating myeloproliferative tumors | 卡托斯医疗公司 | 2021-05-14 | — | — | CN | disclosed |
| WO-2016024230-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, AND/OR A BCL-2 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| EP-2137186-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2016-01-27 | — | — | EP | disclosed |
| WO-2015083008-A1 | THERAPEUTIC COMBINATION OF A PI3K INHIBITOR AND A BTK INHIBITOR | ACERTA PHARMA B.V. (NL) | 2015-06-11 | — | — | WO | disclosed |
| US-20150045361-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2015-02-12 | — | — | US | disclosed |
| US-8901135-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8586739-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220585-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | JAK2, JAK1, MPL | PIK3CG 146/4885PIK3CD 97/4885PIK3CA 20/4885 |
| US-20220054472-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, JAK1, PDPK1 | PIK3CG 47/4885PIK3CD 37/4885PIK3CA 14/4885 |
| US-20090137581-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | PIK3CG 54/4885PIK3CD 16/4885PIK3CA 26/4885 |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | JAK2, JAK1, PDPK1 | PIK3CG 47/4885PIK3CD 37/4885PIK3CA 14/4885 |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CG 54/4885PIK3CD 16/4885PIK3CA 26/4885 |
| US-11166951-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | PIK3CG 18/4885PIK3CD 10/4885PIK3CA 33/4885 |
| US-20220088013-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | BTK, JAK2, BCL9 | PIK3CG 18/4885PIK3CD 10/4885PIK3CA 33/4885 |
| US-20150045361-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CG 54/4885PIK3CD 16/4885PIK3CA 26/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | PIK3CG 302/4885PIK3CD 202/4885PIK3CA 52/4885 |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | PIK3CG 18/4885PIK3CD 10/4885PIK3CA 33/4885 |
| US-20120220585-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CG 54/4885PIK3CD 16/4885PIK3CA 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.